信达生物业绩出色。8月7日，信达生物公告称，上半年总产品收入超52亿元，同比增超35%；第二季度产品收入超27亿元，同比增长超30%。礼来减重药物效果不及预期。8月7日，礼来的首个小分子口服GLP -1药物Orforglipron在72周试验中达成全部目标，实现平均减重11.2%。该结果公布后，公司美股盘前一度跌超12%。在过去的一天里，国内外医药市场还有哪些热点值得关注？让氨基君带你一探究竟。/...
Source Link信达生物业绩出色。8月7日，信达生物公告称，上半年总产品收入超52亿元，同比增超35%；第二季度产品收入超27亿元，同比增长超30%。礼来减重药物效果不及预期。8月7日，礼来的首个小分子口服GLP -1药物Orforglipron在72周试验中达成全部目标，实现平均减重11.2%。该结果公布后，公司美股盘前一度跌超12%。在过去的一天里，国内外医药市场还有哪些热点值得关注？让氨基君带你一探究竟。/...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.